Total Payments
$601.36
2024 Payments
$397.36
Companies
10
Transactions
19
Medicare Patients
568
Medicare Billing
$153,911
Payment Breakdown by Category
Food & Beverage$403.37 (67.1%)
Education$197.99 (32.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $403.37 | 17 | 67.1% |
| Education | $197.99 | 2 | 32.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $160.99 | 3 | $0 (2024) |
| PFIZER INC. | $108.61 | 6 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $99.99 | 1 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $61.18 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $44.65 | 2 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $44.19 | 1 | $0 (2024) |
| Seagen Inc. | $25.87 | 1 | $0 (2023) |
| SOBI, INC | $24.78 | 1 | $0 (2024) |
| TerSera Therapeutics LLC | $16.37 | 1 | $0 (2024) |
| Lilly USA, LLC | $14.73 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $397.36 | 13 | Astellas Pharma US Inc ($160.99) |
| 2023 | $59.36 | 3 | PFIZER INC. ($33.49) |
| 2022 | $44.65 | 2 | Daiichi Sankyo Inc. ($44.65) |
| 2019 | $99.99 | 1 | Alexion Pharmaceuticals, Inc. ($99.99) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.01 | General |
| 09/20/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/25/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $44.19 | General |
| Category: Oncology | ||||||
| 06/18/2024 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/14/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $32.73 | General |
| Category: Infectious Diseases | ||||||
| 05/09/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Oncology | ||||||
| 04/18/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/09/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $98.00 | General |
| 03/26/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/20/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Oncology | ||||||
| 03/12/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 03/08/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $30.26 | General |
| Category: Infectious Diseases | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $36.17 | General |
| 12/05/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/25/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/08/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: Oncology | ||||||
| 12/07/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Iron Deficiency Anemia | ||||||
| 05/12/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: Iron Deficiency Anemia | ||||||
| 02/25/2019 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 177 | 491 | $153,455 | $53,410 |
| 2022 | 7 | 224 | 519 | $162,155 | $55,551 |
| 2021 | 7 | 167 | 421 | $122,625 | $44,950 |
Total Patients
568
Total Services
1,431
Medicare Billing
$153,911
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 236 | $67,980 | $26,205 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 146 | $52,560 | $16,311 | 31.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 62 | $15,235 | $4,842 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $7,120 | $2,535 | 35.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $5,700 | $2,050 | 36.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $4,860 | $1,467 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 210 | $56,700 | $20,348 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 61 | 173 | $62,450 | $20,167 | 32.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 51 | $12,495 | $4,197 | 33.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 33 | 33 | $9,900 | $3,436 | 34.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $8,900 | $3,190 | 35.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 14 | $7,210 | $2,634 | 36.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 17 | 18 | $4,500 | $1,579 | 35.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 40 | 250 | $66,015 | $23,892 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 82 | $26,710 | $9,918 | 37.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $9,335 | $3,584 | 38.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 14 | $7,150 | $2,518 | 35.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 22 | $5,020 | $1,940 | 38.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 16 | 16 | $4,160 | $1,564 | 37.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 15 | 15 | $4,235 | $1,534 | 36.2% |
About Dr. Thomas Jandl, M.D
Dr. Thomas Jandl, M.D is a Hematology & Oncology healthcare provider based in Stony Brook, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2014. The National Provider Identifier (NPI) number assigned to this provider is 1306265301.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Jandl, M.D has received a total of $601.36 in payments from pharmaceutical and medical device companies, with $397.36 received in 2024. These payments were reported across 19 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($403.37).
As a Medicare-enrolled provider, Jandl has provided services to 568 Medicare beneficiaries, totaling 1,431 services with total Medicare billing of $153,911. Data is available for 3 years (2021–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Stony Brook, NY
- Active Since 04/08/2014
- Last Updated 09/16/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1306265301
Products in Payments
- BOSULIF (Drug) $108.61
- Soliris (Drug) $99.99
- Cresemba (Drug) $62.99
- INJECTAFER (Drug) $44.65
- REZUROCK (Drug) $44.19
- ADCETRIS (Biological) $25.87
- DOPTELET (Drug) $24.78
- Zoladex (Drug) $16.37
- VERZENIO (Drug) $14.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Stony Brook
Dr. Jules Cohen, M.d, M.D
Hematology & Oncology — Payments: $520,081
Hematology & Oncology $520,081
Achuta Guddati, Md, MD
Hematology & Oncology — Payments: $1,873
Hematology & Oncology $1,873
Dr. Christina Lee, M.d, M.D
Hematology & Oncology — Payments: $1,111
Hematology & Oncology $1,111
Huda Salman, M.d, M.D
Hematology & Oncology — Payments: $532.26
Hematology & Oncology $532.26
Dr. Judy Huang, Do, DO
Hematology & Oncology — Payments: $497.15
Hematology & Oncology $497.15
Anna Andrzejczyk
Hematology & Oncology — Payments: $473.57
Hematology & Oncology $473.57